Mereo Biopharma Group Plc - ADR
MREO
Get informed when a big investor buys or sells
+ FollowMarket Cap$47.34M
Close$
$0.26
23.6% downside
Current Fair Value
23.6% downsideOvervalued by 23.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.34 Million |
|---|---|
| Enterprise Value | $11.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.26 |
| Beta | 0.28 |
| Outstanding Shares | 160,361,114 |
Return
| Return on Equity | -104.83% |
|---|---|
| Return on Assets | -87.90% |
| Return on Invested Capital | -120.81% |
Valuation & Multiples
| P/E Ratio | -1.32 |
|---|---|
| PEG | 2.76 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 22.24 |
| Enterprise Value to EBIT | -0.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$11.67 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$3.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3338▲ 6.31% |
|---|---|
| Total Calls | 672,200▼ 81.87% |
| Total Puts | 224,400▼ 77.65% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.28%▲ 8.51% |
|---|---|
| Total Invested | $24.87M▼ 3.70% |
| Investors Holding | 67▼ 11.00% |
ESG Score
No data
About Mereo Biopharma Group Plc
2,020 employees
CEO: Denise Pollard-Knight Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. The Company has developed a portfolio of six clinical...